Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes

• Published in: Diabetes research and clinical practice 1999-08, Vol.45 (1), p.31-39
• Main Authors: Damsbo, Peter, Marbury, Thomas C., Hatorp, Vibeke, Clauson, Per, Müller, Peter G.
• Format: Article
• Language: English
• Subjects: Aged; Area Under Curve; Biological and medical sciences; Blood Glucose - metabolism; Carbamates - administration & dosage; Carbamates - standards; Carbamates - therapeutic use; Cholesterol - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Eating - physiology; Female; Fructosamine - blood; Hormones. Endocrine system; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - standards; Hypoglycemic Agents - therapeutic use; Indicators and Reagents - chemistry; Male; Medical sciences; Middle Aged; Nitroblue Tetrazolium - chemistry; Pharmacology. Drug treatments; Piperidines - administration & dosage; Piperidines - standards; Piperidines - therapeutic use; Prandial glucose regulation; Prospective Studies; Repaglinide; Triglycerides - blood; Type 2 diabetes
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/S0168-8227(99)00057-1

Repaglinide is a novel, rapid-acting prandial glucose regulator. To investigate the effect of repaglinide, 1 mg before each meal, in maintaining glycaemic control in Type 2 diabetic patients who either miss a meal or have an extra meal, 25 patients were randomized to either a fixed-meal regimen of three meals/day or one of two mixed-meal regimens consisting of repeating patterns of two, three or four meals/day over a 20-day period. On the 21st day each patient received three meals. Overall glycaemic control was assessed by weekly serum fructosamine concentrations and 13-point and 37-point serum glucose profiles. Mean fructosamine concentrations decreased significantly to normal values during the treatment period (from 3.10 to 2.68 mg/dl on the fixed-meal regimen and from 3.37 to 2.85 mg/dl on the mixed-meal regimens; P